Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 1Liver Neoplasms 1Hematologic Neoplasms 1Hematologic Diseases 1Carcinoma, Hepatocellular 1

Interventions

pirtobrutinib 5Tacrolimus 3Rituximab 3Mycophenolic Acid 3Cyclophosphamide 3venetoclax 2fludarabine phosphate 2fludarabine 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Melphalan 2Busulfan 2Bendamustine Hydrochloride 2zanubrutinib 1isatuximab 1idelalisib 1ibrutinib 1acalabrutinib 1Vorinostat 1Ustekinumab 1Transplantation Conditioning 1Methotrexate 1Lenalidomide 1Interleukin-12 Subunit p40 1Immunoglobulin G 1Geriatric Assessment 1Disulfides 1Cyclosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Hematologic Diseases × Cell- and Tissue-Based Therapy × Clear all
NCT06849921 2025-02-27

Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors

Ruijin Hospital

Phase NA Active not recruiting
200 enrolled
Other hematologic neoplasm

Hematologic Diseases, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡